Richeek Pradhan, McGill University

Research

Drug Effectiveness Drug Safety Frailty Glp-1 Receptor Agonists Older Patients Population-Based Type 2 Diabetes

Latest papers

Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
Diabetic medicine : a journal of the British Diabetic Association · 2024 · first author
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.
BMJ open diabetes research & care · 2023 · first author
Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study.
Gut · 2023

All 14 publications

Latest funding

GLP-1 Receptor Agonists in Older Adults: Weighing Cardiovascular Benefits Against Frailty-Related Risks
CIHR · 2025 · Principal investigator
$397,800
The Use of Incretin-Based Drugs and SGLT-2 Inhibitors for the Prevention of Parkinson's Disease Among Patients with Type 2 Diabetes
CIHR · 2023 · Co-investigator
$252,450
The Use of GLP-1 Receptor Agonists and SGLT-2 Inhibitors for the Long-term Prevention of Liver Complications Among Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
CIHR · 2021 · Co-investigator
$164,476

All 3 grants and awards

14 publications.

01

Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.

Pradhan R, Yu OHY, Platt RW, Azoulay L

Diabetic medicine : a journal of the British Diabetic Association2024First author

DOI: 10.1111/dme.15248 PMID: 37876318

02

Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.

Pradhan R, Yu OHY, Platt RW, Azoulay L

BMJ open diabetes research & care2023First author

DOI: 10.1136/bmjdrc-2023-003550 PMID: 37949470

03

Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study.

Abrahami D, Pradhan R, Yin H, Yanofsky R, McDonald EG, Bitton A, Azoulay L

Gut2023

DOI: 10.1136/gutjnl-2022-328866 PMID: 36717221

04

Associations Between Natural Language Processing-Enriched Social Determinants of Health and Suicide Death Among US Veterans.

Mitra A, Pradhan R, Melamed RD, Chen K, Hoaglin DC, Tucker KL, Reisman JI, Yang Z, Liu W, Tsai J, Yu H

JAMA network open2023

DOI: 10.1001/jamanetworkopen.2023.3079 PMID: 36920391

05

Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.

Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S, Azoulay L

BMJ (Clinical research ed.)2022First author

DOI: 10.1136/bmj-2022-071380 PMID: 36318979

06

Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes.

Pradhan R, Yin H, Yu OHY, Azoulay L

Diabetes care2022First author

DOI: 10.2337/dc22-0712 PMID: 35866685

07

India's ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?

Sulis G, Pradhan R, Kotwani A, Gandra S

Journal of pharmaceutical policy and practice2022

DOI: 10.1186/s40545-022-00428-w PMID: 35484606

08

Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.

Pradhan R, Yin H, Yu O, Azoulay L

Diabetes care2022First author

DOI: 10.2337/dc21-1953 PMID: 35104330

09

Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom.

Pradhan R, Yu O, Platt RW, Azoulay L

Diabetes research and clinical practice2022First author

DOI: 10.1016/j.diabres.2022.109229 PMID: 35124095

10

Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.

Pradhan R, Abrahami D, Yin H, Yu OHY, Sahasrabudhe V, Baumfeld Andre E, Azoulay L

Clinical pharmacology and therapeutics2021First author

DOI: 10.1002/cpt.2213 PMID: 33615445

GLP-1 Receptor Agonists in Older Adults: Weighing Cardiovascular Benefits Against Frailty-Related Risks

Principal investigatorCIHR2025Project Grant

Principal investigators: Azoulay, Laurent; Pradhan, Richeek

Keywords: Drug Effectiveness; Drug Safety; Frailty; Glp-1 Receptor Agonists; Older Patients; Population-Based; Type 2 Diabetes

$397,800

The Use of Incretin-Based Drugs and SGLT-2 Inhibitors for the Prevention of Parkinson's Disease Among Patients with Type 2 Diabetes

Co-investigatorCIHR2023Project Grant

Principal investigators: Renoux, Christel; Azoulay, Laurent

Keywords: Cohort Study; Electronic Medical Records; Incretin-Based Drugs; Parkinson'S Disease; Pharmacoepidemiology; Sglt-2 Inhibitors

$252,450

The Use of GLP-1 Receptor Agonists and SGLT-2 Inhibitors for the Long-term Prevention of Liver Complications Among Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Co-investigatorCIHR2021Project Grant

Principal investigators: Azoulay, Laurent

Keywords: Cirrhosis; Drug Effectiveness; Glp-1 Receptor Agonists; Hepatocellular Carcinoma; Non-Alcoholic Fatty Liver Disease; Population-Based; Sglt-2 Inhibitors; Type 2 Diabetes

$164,476

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Oncology
Endocrinology and Metabolism
Medicine
Other

Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Oriana Yu

Endocrinology and Metabolism

2 shared papers, latest 2022

Alain Bitton

Faculty

1 shared papers, latest 2023

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Drug Effectiveness Dear Professor Pradhan, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study." (2024), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "GLP-1 Receptor Agonists in Older Adults: Weighing Cardiovascular Benefits Against Frailty-Related Risks" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Richeek Pradhan